The fund seeks capital appreciation in the long term by investing in companies across any size in the United States.

The investment process is designed to identify companies in the benchmark index that experience positive dynamic change.

The investment team believes companies undergoing positive dynamic change offer the best investment opportunities.

Next, the research team utilizes fundamental analysis to uncover companies experiencing high unit volume growth and positive changes in product cycle and market dynamics.

The team also focuses on traditional growth companies experiencing rapidly growing demand or market dominance.

In addition, the research team emphasizes companies benefitting from new regulations, a new product innovation or new management.

Then the research process relies on fundamental analysis to highlight companies that are engaged in the health sciences sector demonstrating growth potential.

The team considers a company to be engaged in the health sciences sector if it derives at least 50% of its earnings or revenues from, or devotes at least 50% of its assets to activities in any area of the health sciences sector, including health care services, pharmaceuticals, medical equipment and supplies and applied research and development.

Additionally, the team considers companies involved with hospitals, clinical test laboratories, convalescent and mental health care facilities, home care providers, pharmaceuticals, biotechnology, biochemistry and diagnostics; and producers and manufacturers of medical, dental and optical supplies and equipment as part of the health sciences sector.

Then the manager constructs a diversified portfolio from a list of companies favored by the research team and allocates capital based on its conviction level.

The fund has the flexibility to invest in securities of foreign issuers.

The fund seeks capital appreciation in the long term by investing in companies across any size in the United States.

The investment process is designed to identify companies in the benchmark index that experience positive dynamic change.

The investment team believes companies undergoing positive dynamic change offer the best investment opportunities.

Next, the research team utilizes fundamental analysis to uncover companies experiencing high unit volume growth and positive changes in product cycle and market dynamics.

The team also focuses on traditional growth companies experiencing rapidly growing demand or market dominance.

In addition, the research team emphasizes companies benefitting from new regulations, a new product innovation or new management.

Then the research process relies on fundamental analysis to highlight companies that are engaged in the health sciences sector demonstrating growth potential.

The team considers a company to be engaged in the health sciences sector if it derives at least 50% of its earnings or revenues from, or devotes at least 50% of its assets to activities in any area of the health sciences sector, including health care services, pharmaceuticals, medical equipment and supplies and applied research and development.

Additionally, the team considers companies involved with hospitals, clinical test laboratories, convalescent and mental health care facilities, home care providers, pharmaceuticals, biotechnology, biochemistry and diagnostics; and producers and manufacturers of medical, dental and optical supplies and equipment as part of the health sciences sector.

Then the manager constructs a diversified portfolio from a list of companies favored by the research team and allocates capital based on its conviction level.

The fund has the flexibility to invest in securities of foreign issuers.

The fund seeks capital appreciation in the long term by investing in companies across any size in the United States.

The investment process is designed to identify companies in the benchmark index that experience positive dynamic change.

The investment team believes companies undergoing positive dynamic change offer the best investment opportunities.

Next, the research team utilizes fundamental analysis to uncover companies experiencing high unit volume growth and positive changes in product cycle and market dynamics.

The team also focuses on traditional growth companies experiencing rapidly growing demand or market dominance.

In addition, the research team emphasizes companies benefitting from new regulations, a new product innovation or new management.

Then the research process relies on fundamental analysis to highlight companies that are engaged in the health sciences sector demonstrating growth potential.

The team considers a company to be engaged in the health sciences sector if it derives at least 50% of its earnings or revenues from, or devotes at least 50% of its assets to activities in any area of the health sciences sector, including health care services, pharmaceuticals, medical equipment and supplies and applied research and development.

Additionally, the team considers companies involved with hospitals, clinical test laboratories, convalescent and mental health care facilities, home care providers, pharmaceuticals, biotechnology, biochemistry and diagnostics; and producers and manufacturers of medical, dental and optical supplies and equipment as part of the health sciences sector.

Then the manager constructs a diversified portfolio from a list of companies favored by the research team and allocates capital based on its conviction level.

The fund has the flexibility to invest in securities of foreign issuers.

The fund seeks to invest in healthcare companies providing services, engaged in research and development and medical products makers and distributors.

The fund looks for opportunities in all market capitalization and builds a concentrated portfolio of high convictions names. Most of the fund’s investments are in large- and mid-cap segment of the market but the fund also invests in early stage biotech development companies as well.

The number of healthcare companies available to invest are expected to rise significantly with the ageing population and faster regulatory drug approvals in the U.S., and early stage biotech companies enjoying growing access to risk capital for advanced research.

The fund seeks to invest in healthcare companies providing services, engaged in research and development and medical products makers and distributors.

The fund looks for opportunities in all market capitalization and builds a concentrated portfolio of high convictions names. Most of the fund’s investments are in large- and mid-cap segment of the market but the fund also invests in early stage biotech development companies as well.

The number of healthcare companies available to invest are expected to rise significantly with the ageing population and faster regulatory drug approvals in the U.S., and early stage biotech companies enjoying growing access to risk capital for advanced research.

The fund seeks to invest in healthcare companies providing services, engaged in research and development and medical products makers and distributors.

The fund looks for opportunities in all market capitalization and builds a concentrated portfolio of high convictions names. Most of the fund’s investments are in large- and mid-cap segment of the market but the fund also invests in early stage biotech development companies as well.

The number of healthcare companies available to invest are expected to rise significantly with the ageing population and faster regulatory drug approvals in the U.S., and early stage biotech companies enjoying growing access to risk capital for advanced research.

The fund seeks capital appreciation in the long term by investing in companies in the United States.

The investment process is driven by fundamental techniques to identify companies in health sciences and related industries.

Then the research team companies in health care equipment and supplies, health care providers and services, biotechnology, and pharmaceuticals as related to the health sciences sector.

The team also focuses on companies involved in the development, production, and distribution or delivery of medical and pharmaceutical products and services and engaged in biotechnology and medical research and development.

In addition, the team also emphasizes companies that may design, manufacture or distribute medical, dental and optical equipment and supplies, including diagnostic equipment.

The team also seeks to invest in companies that may also provide diagnostic services or operate health facilities and hospitals, or provide related administrative, management and financial support.

Then the manager constructs a portfolio from a list of companies in the benchmark index favored by the research team and allocates capital based on its conviction level.

The manager will invest more than 25% of its net assets in health sciences or related industries, and may invest in companies located in non-U.S. countries.

The fund may also invest up to 20% of its net assets in stocks of companies not associated with health sciences.

The fund seeks capital appreciation in the long term by investing in companies in the United States.

The investment process is driven by fundamental techniques to identify companies in health sciences and related industries.

Then the research team companies in health care equipment and supplies, health care providers and services, biotechnology, and pharmaceuticals as related to the health sciences sector.

The team also focuses on companies involved in the development, production, and distribution or delivery of medical and pharmaceutical products and services and engaged in biotechnology and medical research and development.

In addition, the team also emphasizes companies that may design, manufacture or distribute medical, dental and optical equipment and supplies, including diagnostic equipment.

The team also seeks to invest in companies that may also provide diagnostic services or operate health facilities and hospitals, or provide related administrative, management and financial support.

Then the manager constructs a portfolio from a list of companies in the benchmark index favored by the research team and allocates capital based on its conviction level.

The manager will invest more than 25% of its net assets in health sciences or related industries, and may invest in companies located in non-U.S. countries.

The fund may also invest up to 20% of its net assets in stocks of companies not associated with health sciences.

The fund seeks capital appreciation in the long term by investing in companies in the United States.

The investment process is driven by fundamental techniques to identify companies in health sciences and related industries.

Then the research team companies in health care equipment and supplies, health care providers and services, biotechnology, and pharmaceuticals as related to the health sciences sector.

The team also focuses on companies involved in the development, production, and distribution or delivery of medical and pharmaceutical products and services and engaged in biotechnology and medical research and development.

In addition, the team also emphasizes companies that may design, manufacture or distribute medical, dental and optical equipment and supplies, including diagnostic equipment.

The team also seeks to invest in companies that may also provide diagnostic services or operate health facilities and hospitals, or provide related administrative, management and financial support.

Then the manager constructs a portfolio from a list of companies in the benchmark index favored by the research team and allocates capital based on its conviction level.

The manager will invest more than 25% of its net assets in health sciences or related industries, and may invest in companies located in non-U.S. countries.

The fund may also invest up to 20% of its net assets in stocks of companies not associated with health sciences.

The fund seeks capital appreciation in the long term by investing in companies in the United States.

The investment process is driven by fundamental techniques to identify companies in health sciences and related industries.

Then the research team companies in health care equipment and supplies, health care providers and services, biotechnology, and pharmaceuticals as related to the health sciences sector.

The team also focuses on companies involved in the development, production, and distribution or delivery of medical and pharmaceutical products and services and engaged in biotechnology and medical research and development.

In addition, the team also emphasizes companies that may design, manufacture or distribute medical, dental and optical equipment and supplies, including diagnostic equipment.

The team also seeks to invest in companies that may also provide diagnostic services or operate health facilities and hospitals, or provide related administrative, management and financial support.

Then the manager constructs a portfolio from a list of companies in the benchmark index favored by the research team and allocates capital based on its conviction level.

The manager will invest more than 25% of its net assets in health sciences or related industries, and may invest in companies located in non-U.S. countries.

The fund may also invest up to 20% of its net assets in stocks of companies not associated with health sciences.

The fund seeks capital appreciation in the long term by investing in companies in the United States.

The investment process is driven by fundamental techniques to identify companies in health sciences and related industries.

Then the research team companies in health care equipment and supplies, health care providers and services, biotechnology, and pharmaceuticals as related to the health sciences sector.

The team also focuses on companies involved in the development, production, and distribution or delivery of medical and pharmaceutical products and services and engaged in biotechnology and medical research and development.

In addition, the team also emphasizes companies that may design, manufacture or distribute medical, dental and optical equipment and supplies, including diagnostic equipment.

The team also seeks to invest in companies that may also provide diagnostic services or operate health facilities and hospitals, or provide related administrative, management and financial support.

Then the manager constructs a portfolio from a list of companies in the benchmark index favored by the research team and allocates capital based on its conviction level.

The manager will invest more than 25% of its net assets in health sciences or related industries, and may invest in companies located in non-U.S. countries.

The fund may also invest up to 20% of its net assets in stocks of companies not associated with health sciences.

The fund seeks capital appreciation in the long term by investing in companies in the United States.

The investment process is driven by fundamental techniques to identify companies in health sciences and related industries.

Then the research team companies in health care equipment and supplies, health care providers and services, biotechnology, and pharmaceuticals as related to the health sciences sector.

The team also focuses on companies involved in the development, production, and distribution or delivery of medical and pharmaceutical products and services and engaged in biotechnology and medical research and development.

In addition, the team also emphasizes companies that may design, manufacture or distribute medical, dental and optical equipment and supplies, including diagnostic equipment.

The team also seeks to invest in companies that may also provide diagnostic services or operate health facilities and hospitals, or provide related administrative, management and financial support.

Then the manager constructs a portfolio from a list of companies in the benchmark index favored by the research team and allocates capital based on its conviction level.

The manager will invest more than 25% of its net assets in health sciences or related industries, and may invest in companies located in non-U.S. countries.

The fund may also invest up to 20% of its net assets in stocks of companies not associated with health sciences.

The healthcare focused fund looks for investment opportunities around the world including emerging markets.

Investment process of the fund is designed to discover companies with attractive business franchise, stocks trading at attractive valuations and significant long-term growth potential.

The diversified fund invests in large and small medical products makers and biotech companies, large health insurance services providers and medical distributors.

The fund allocates its assets across more than 100 companies and top 10 holdings account for 45%.

The healthcare focused fund looks for investment opportunities around the world including emerging markets.

Investment process of the fund is designed to discover companies with attractive business franchise, stocks trading at attractive valuations and significant long-term growth potential.

The diversified fund invests in large and small medical products makers and biotech companies, large health insurance services providers and medical distributors.

The fund allocates its assets across more than 100 companies and top 10 holdings account for 45%.

The healthcare focused fund looks for investment opportunities around the world including emerging markets.

Investment process of the fund is designed to discover companies with attractive business franchise, stocks trading at attractive valuations and significant long-term growth potential.

The diversified fund invests in large and small medical products makers and biotech companies, large health insurance services providers and medical distributors.

The fund allocates its assets across more than 100 companies and top 10 holdings account for 45%.

The healthcare focused fund looks for investment opportunities around the world including emerging markets.

Investment process of the fund is designed to discover companies with attractive business franchise, stocks trading at attractive valuations and significant long-term growth potential.

The diversified fund invests in large and small medical products makers and biotech companies, large health insurance services providers and medical distributors.

The fund allocates its assets across more than 100 companies and top 10 holdings account for 45%.

The fund seeks to appreciate capital in the long-term by investing in the healthcare industry and companies promoting healthy lifestyle.

The investment process includes companies in the healthcare industry and other companies that provide products or services that promote or aid in achieving a healthy lifestyle. The fund concentrates at least 25% of its net assets in the healthcare sector and may invest up to 20% in U.S. Treasurys and government agency debts.

The investment process with the help of quantitative screens and analytical techniques narrows the list of investable companies to those with above-average earnings growth, high return on capital and strong financial statements. The team reviews individual companies for the quality of products or services portfolio, management and long-term sustainability of businesses.

The fund favors companies with unique products, above-average earnings growth and sustainable businesses trading at reasonable prices.

The fund seeks to appreciate capital in the long-term by investing in the healthcare industry and companies promoting healthy lifestyle.

The investment process includes companies in the healthcare industry and other companies that provide products or services that promote or aid in achieving a healthy lifestyle. The fund concentrates at least 25% of its net assets in the healthcare sector and may invest up to 20% in U.S. Treasurys and government agency debts.

The investment process with the help of quantitative screens and analytical techniques narrows the list of investable companies to those with above-average earnings growth, high return on capital and strong financial statements. The team reviews individual companies for the quality of products or services portfolio, management and long-term sustainability of businesses.

The fund favors companies with unique products, above-average earnings growth and sustainable businesses trading at reasonable prices.

The fund seeks to appreciate capital in the long-term by investing in the healthcare industry and companies promoting healthy lifestyle.

The investment process includes companies in the healthcare industry and other companies that provide products or services that promote or aid in achieving a healthy lifestyle. The fund concentrates at least 25% of its net assets in the healthcare sector and may invest up to 20% in U.S. Treasurys and government agency debts.

The investment process with the help of quantitative screens and analytical techniques narrows the list of investable companies to those with above-average earnings growth, high return on capital and strong financial statements. The team reviews individual companies for the quality of products or services portfolio, management and long-term sustainability of businesses.

The fund favors companies with unique products, above-average earnings growth and sustainable businesses trading at reasonable prices.

The fund seeks to appreciate capital in the long-term by investing in the healthcare industry and companies promoting healthy lifestyle.

The investment process includes companies in the healthcare industry and other companies that provide products or services that promote or aid in achieving a healthy lifestyle. The fund concentrates at least 25% of its net assets in the healthcare sector and may invest up to 20% in U.S. Treasurys and government agency debts.

The investment process with the help of quantitative screens and analytical techniques narrows the list of investable companies to those with above-average earnings growth, high return on capital and strong financial statements. The team reviews individual companies for the quality of products or services portfolio, management and long-term sustainability of businesses.

The fund favors companies with unique products, above-average earnings growth and sustainable businesses trading at reasonable prices.

The fund seeks capital appreciation in the long term by investing in companies across any size in the United States.

The investment process is relies on fundamental analysis to identify companies in healthcare and life sciences companies.

Healthcare and life sciences companies include those companies that derive or are expected to derive 50% or more of their revenue from healthcare and life science products and services including, but not limited to, biotechnology, pharmaceuticals, diagnostics, life science tools, medical devices, healthcare information technology, healthcare services, synthetic biology, agricultural and environmental management, and pharmaceutical manufacturing products and services.

Next, the research team focuses on companies with attractive valuations exhibiting above-average long-term investment opportunities or significant near-term appreciation potential.

Then the manager constructs a portfolio from a list of companies in the benchmark index favored by the research team and allocates capital based on its conviction level.

The manager invests over 25% of the fund’s net assets in drug related industries. This group of industries includes pharmaceutical, biotech and similar companies that primarily develop, produce or distribute drugs, medicines, diagnostic chemicals and biological products used to diagnose, prevent or treat diseases or maintain health.

The fund invests in companies that demonstrate values and business practices that are ethical, sustainable, and provide an attractive investment opportunity.

The fund looks for companies that respect the value and freedom of all people, demonstrate a concern for justice and peace, promote family and community, demonstrate responsible management practices, and practice environmental stewardship.

However, the fund may invest in companies that fund community development institutions and serve needs of low-to-moderate income families and communities.

The fund may invest without limitation in companies domiciled outside the United States either directly or through American Depositary Receipts.

The fund seeks capital appreciation in the long term by investing in companies across any size in the United States.

The investment process is relies on fundamental analysis to identify companies in healthcare and life sciences companies.

Healthcare and life sciences companies include those companies that derive or are expected to derive 50% or more of their revenue from healthcare and life science products and services including, but not limited to, biotechnology, pharmaceuticals, diagnostics, life science tools, medical devices, healthcare information technology, healthcare services, synthetic biology, agricultural and environmental management, and pharmaceutical manufacturing products and services.

Next, the research team focuses on companies with attractive valuations exhibiting above-average long-term investment opportunities or significant near-term appreciation potential.

Then the manager constructs a portfolio from a list of companies in the benchmark index favored by the research team and allocates capital based on its conviction level.

The manager invests over 25% of the fund’s net assets in drug related industries. This group of industries includes pharmaceutical, biotech and similar companies that primarily develop, produce or distribute drugs, medicines, diagnostic chemicals and biological products used to diagnose, prevent or treat diseases or maintain health.

The fund invests in companies that demonstrate values and business practices that are ethical, sustainable, and provide an attractive investment opportunity.

The fund looks for companies that respect the value and freedom of all people, demonstrate a concern for justice and peace, promote family and community, demonstrate responsible management practices, and practice environmental stewardship.

However, the fund may invest in companies that fund community development institutions and serve needs of low-to-moderate income families and communities.

The fund may invest without limitation in companies domiciled outside the United States either directly or through American Depositary Receipts.

The fund seeks capital appreciation in the long term by investing in companies across any size in the United States.

The investment process is relies on fundamental analysis to identify companies in healthcare and life sciences companies.

Healthcare and life sciences companies include those companies that derive or are expected to derive 50% or more of their revenue from healthcare and life science products and services including, but not limited to, biotechnology, pharmaceuticals, diagnostics, life science tools, medical devices, healthcare information technology, healthcare services, synthetic biology, agricultural and environmental management, and pharmaceutical manufacturing products and services.

Next, the research team focuses on companies with attractive valuations exhibiting above-average long-term investment opportunities or significant near-term appreciation potential.

Then the manager constructs a portfolio from a list of companies in the benchmark index favored by the research team and allocates capital based on its conviction level.

The manager invests over 25% of the fund’s net assets in drug related industries. This group of industries includes pharmaceutical, biotech and similar companies that primarily develop, produce or distribute drugs, medicines, diagnostic chemicals and biological products used to diagnose, prevent or treat diseases or maintain health.

The fund invests in companies that demonstrate values and business practices that are ethical, sustainable, and provide an attractive investment opportunity.

The fund looks for companies that respect the value and freedom of all people, demonstrate a concern for justice and peace, promote family and community, demonstrate responsible management practices, and practice environmental stewardship.

However, the fund may invest in companies that fund community development institutions and serve needs of low-to-moderate income families and communities.

The fund may invest without limitation in companies domiciled outside the United States either directly or through American Depositary Receipts.

The fund seeks capital appreciation in the long term by investing in companies across any size in the United States.

The investment process is relies on fundamental analysis to identify companies in healthcare and life sciences companies.

Healthcare and life sciences companies include those companies that derive or are expected to derive 50% or more of their revenue from healthcare and life science products and services including, but not limited to, biotechnology, pharmaceuticals, diagnostics, life science tools, medical devices, healthcare information technology, healthcare services, synthetic biology, agricultural and environmental management, and pharmaceutical manufacturing products and services.

Next, the research team focuses on companies with attractive valuations exhibiting above-average long-term investment opportunities or significant near-term appreciation potential.

Then the manager constructs a portfolio from a list of companies in the benchmark index favored by the research team and allocates capital based on its conviction level.

The manager invests over 25% of the fund’s net assets in drug related industries. This group of industries includes pharmaceutical, biotech and similar companies that primarily develop, produce or distribute drugs, medicines, diagnostic chemicals and biological products used to diagnose, prevent or treat diseases or maintain health.

The fund invests in companies that demonstrate values and business practices that are ethical, sustainable, and provide an attractive investment opportunity.

The fund looks for companies that respect the value and freedom of all people, demonstrate a concern for justice and peace, promote family and community, demonstrate responsible management practices, and practice environmental stewardship.

However, the fund may invest in companies that fund community development institutions and serve needs of low-to-moderate income families and communities.

The fund may invest without limitation in companies domiciled outside the United States either directly or through American Depositary Receipts.

The fund seeks capital appreciation by investing in companies in the United States.

The investment process is designed to highlight companies that are engaged in the research, development, manufacture, and distribution of various biotechnological products, services, and processes.

The process also focuses on companies that benefit significantly from scientific and technological advances in biotechnology.

Additionally, the research team evaluates a company’s financial condition and industry position, as well as market and economic conditions.

Then the manager constructs a diversified portfolio of stocks from a list of companies in the benchmark index favored by the research team and allocates capital based on its conviction level.

The fund has the flexibility to invest in domestic and foreign issuers.

The fund seeks capital appreciation by investing in companies in the United States.

The investment process is designed to highlight companies that are engaged in the research, development, manufacture, and distribution of various biotechnological products, services, and processes.

The process also focuses on companies that benefit significantly from scientific and technological advances in biotechnology.

Additionally, the research team evaluates a company’s financial condition and industry position, as well as market and economic conditions.

Then the manager constructs a diversified portfolio of stocks from a list of companies in the benchmark index favored by the research team and allocates capital based on its conviction level.

The fund has the flexibility to invest in domestic and foreign issuers.

The fund seeks capital appreciation by investing in companies in the United States.

The investment process is designed to highlight companies that are engaged in the research, development, manufacture, and distribution of various biotechnological products, services, and processes.

The process also focuses on companies that benefit significantly from scientific and technological advances in biotechnology.

Additionally, the research team evaluates a company’s financial condition and industry position, as well as market and economic conditions.

Then the manager constructs a diversified portfolio of stocks from a list of companies in the benchmark index favored by the research team and allocates capital based on its conviction level.

The fund has the flexibility to invest in domestic and foreign issuers.

The fund seeks capital appreciation by investing in companies in the United States.

The investment process is designed to highlight companies that are engaged in the research, development, manufacture, and distribution of various biotechnological products, services, and processes.

The process also focuses on companies that benefit significantly from scientific and technological advances in biotechnology.

Additionally, the research team evaluates a company’s financial condition and industry position, as well as market and economic conditions.

Then the manager constructs a diversified portfolio of stocks from a list of companies in the benchmark index favored by the research team and allocates capital based on its conviction level.

The fund has the flexibility to invest in domestic and foreign issuers.

The fund seeks capital appreciation by investing in companies in the United States.

The investment process is designed to highlight companies that are engaged in the research, development, manufacture, and distribution of various biotechnological products, services, and processes.

The process also focuses on companies that benefit significantly from scientific and technological advances in biotechnology.

Additionally, the research team evaluates a company’s financial condition and industry position, as well as market and economic conditions.

Then the manager constructs a diversified portfolio of stocks from a list of companies in the benchmark index favored by the research team and allocates capital based on its conviction level.

The fund has the flexibility to invest in domestic and foreign issuers.

The fund seeks capital appreciation by investing in companies in the United States.

The investment process is designed to highlight companies that are engaged in the design, manufacture, or sale of products or services used for or in connection with health care or medicine.

Next, the research team evaluates a company’s financial condition and industry position, as well as market and economic conditions.

Then the manager constructs a diversified portfolio of stocks from a list of companies in the benchmark index favored by the research team and allocates capital based on its conviction level.

The fund has the flexibility to invest in domestic and foreign issuers.

The fund seeks capital appreciation by investing in companies in the United States.

The investment process is designed to highlight companies that are engaged in the design, manufacture, or sale of products or services used for or in connection with health care or medicine.

Next, the research team evaluates a company’s financial condition and industry position, as well as market and economic conditions.

Then the manager constructs a diversified portfolio of stocks from a list of companies in the benchmark index favored by the research team and allocates capital based on its conviction level.

The fund has the flexibility to invest in domestic and foreign issuers.

The fund seeks capital appreciation by investing in companies in the United States.

The investment process is designed to highlight companies that are engaged in the design, manufacture, or sale of products or services used for or in connection with health care or medicine.

Next, the research team evaluates a company’s financial condition and industry position, as well as market and economic conditions.

Then the manager constructs a diversified portfolio of stocks from a list of companies in the benchmark index favored by the research team and allocates capital based on its conviction level.

The fund has the flexibility to invest in domestic and foreign issuers.

The fund seeks capital appreciation by investing in companies in the United States.

The investment process is designed to highlight companies that are engaged in the design, manufacture, or sale of products or services used for or in connection with health care or medicine.

Next, the research team evaluates a company’s financial condition and industry position, as well as market and economic conditions.

Then the manager constructs a diversified portfolio of stocks from a list of companies in the benchmark index favored by the research team and allocates capital based on its conviction level.

The fund has the flexibility to invest in domestic and foreign issuers.

The fund seeks capital appreciation by investing in companies in the United States.

The investment process is designed to highlight companies that are engaged in the design, manufacture, or sale of products or services used for or in connection with health care or medicine.

Next, the research team evaluates a company’s financial condition and industry position, as well as market and economic conditions.

Then the manager constructs a diversified portfolio of stocks from a list of companies in the benchmark index favored by the research team and allocates capital based on its conviction level.

The fund has the flexibility to invest in domestic and foreign issuers.

The fund seeks capital appreciation by investing in companies in the United States.

The investment process is designed to highlight companies that are engaged in the research, development, manufacture, and distribution of various biotechnological products, services, and processes.

The process also focuses on companies that benefit significantly from scientific and technological advances in biotechnology.

The strategy seeks to outperform its benchmark index through active management.

Then the research team evaluates a company’s free cash flow and the probability risk-adjusted net present value of future earnings, the standard valuation method in the drug-development industry.

In addition, the team assesses a company's drug pipeline, the size of its market opportunity and its relative valuation.

Next, the research team evaluates a company’s financial condition and industry position, as well as market and economic conditions.

Then the manager constructs a diversified portfolio of stocks from a list of companies in the benchmark index favored by the research team and allocates capital based on its conviction level.

The manager focuses around four major themes such as long-term winners with superior product pipelines, turnaround situations, breakthrough innovations and early-stage firms with promising science.

The fund has the flexibility to invest in domestic and foreign issuers.

The fund seeks capital appreciation by investing in companies in the United States.

The investment process is designed to highlight companies that are engaged in the design, manufacture, or sale of products or services used for or in connection with health care or medicine.

The strategy seeks to outperform its benchmark index through active management.

Then the research process is driven by fundamental analysis of one stock at a time. The research team emphasizes high-quality companies exhibiting consistent earnings growth or producing innovative products that disrupt the marketplace.

Next, the team focuses on factors such as a company’s free cash flow and capital allocation, and also assesses a company’s market opportunity, sales growth and margin outlook.

In addition, the research team evaluates a company’s financial condition and industry position, as well as market and economic conditions.

Then the manager constructs a diversified portfolio of stocks from a list of companies in the benchmark index favored by the research team and allocates capital based on its conviction level.

The fund has the flexibility to invest in domestic and foreign issuers.

The fund seeks capital appreciation by investing in companies in the United States.

The investment process is designed to highlight companies that are engaged in the ownership or management of hospitals, nursing homes, health maintenance organizations, and other companies specializing in the delivery of health care services.

The strategy seeks to outperform its benchmark index through active management.

Next, the research team relies on fundamental analysis to identify companies operated by proven management teams generating a high return on invested capital and cash.

The team prefers companies that are mispriced on a net present value basis with competitive barriers to entry.

Additionally, the research team considers companies that are cheap for temporary reasons but have future capital appreciation potential not yet recognized by the market.

Next, the research team evaluates a company’s financial condition and industry position, as well as market and economic conditions.

Then the manager constructs a diversified portfolio of stocks from a list of companies in the benchmark index favored by the research team and allocates capital based on its conviction level.

The fund has the flexibility to invest in domestic and foreign issuers.

The fund seeks capital appreciation by investing in companies in the United States.

The investment process is designed to highlight companies that are engaged in research, development, manufacture, distribution, supply or sale of medical equipment and devices and related technologies.

The strategy seeks to outperform its benchmark index through active management.

Then the research process is driven by fundamental analysis of one stock at a time. The research team emphasizes high-quality companies exhibiting consistent earnings growth or producing innovative products that disrupt the marketplace.

Next, the team focuses on factors such as a company’s free cash flow and capital allocation, and also assesses a company’s market opportunity, sales growth and margin outlook.

Then the research team also focuses on companies enabling drug discovery, and providing technology services primarily to health care providers. These companies may include manufacturers of health care equipment and supplies including drug delivery systems and eye care products.

The team also seeks to invest in firms providing services directly related to the pharmaceutical and biotechnology industries, and companies providing applications, systems and/or data processing software, and IT consulting services and tools to doctors, hospitals and health care businesses.

In addition, the research team evaluates a company’s financial condition and industry position, as well as market and economic conditions.

Then the manager constructs a diversified portfolio of stocks from a list of companies in the benchmark index favored by the research team and allocates capital based on its conviction level.

The fund has the flexibility to invest in domestic and foreign issuers.

The fund seeks capital appreciation by investing in small-size companies in the United States.

The investment process is designed to highlight biotechnology companies and discovery research firms.

The investment team considers a biotechnology company or discovery research firm is one that has at least 50% of its earnings derived from biotechnology activities, or at least 50% of its assets devoted to such activities, based on the company’s most recent fiscal year.

Next, the research team considers discovery research firms are in the early stages of drug research.

Also, according to the team biotechnology activities are research, development, manufacture, and distribution of various biotechnological or biomedical products, services, and processes. This may include companies involved with genomics, genetic engineering, gene therapy, and companies involved in the application and development of biotechnology in areas such as health care, pharmaceuticals, and agriculture.

Then the research process is driven by fundamental analysis of one stock at a time. The research team focuses on companies that exhibit future earnings growth potential at attractive valuations.

In addition, the team prefers companies that generate consistent earnings, cash flow, and income.

Then the manager constructs a diversified portfolio of stocks from a list of companies in the benchmark index favored by the research team and allocates capital based on its conviction level.

The fund is non-diversified, which means it may invest a greater portion of its net assets in the securities of one or more issuers and invests overall in a smaller number of issuers than a diversified fund.

The fund has the flexibility to buy foreign securities that are traded in the U.S. or in foreign markets, as well as American, European, and Global Depositary Receipts.

The fund seeks capital appreciation by investing in small-size companies in the United States.

The investment process is designed to highlight biotechnology companies and discovery research firms.

The investment team considers a biotechnology company or discovery research firm is one that has at least 50% of its earnings derived from biotechnology activities, or at least 50% of its assets devoted to such activities, based on the company’s most recent fiscal year.

Next, the research team considers discovery research firms are in the early stages of drug research.

Also, according to the team biotechnology activities are research, development, manufacture, and distribution of various biotechnological or biomedical products, services, and processes. This may include companies involved with genomics, genetic engineering, gene therapy, and companies involved in the application and development of biotechnology in areas such as health care, pharmaceuticals, and agriculture.

Then the research process is driven by fundamental analysis of one stock at a time. The research team focuses on companies that exhibit future earnings growth potential at attractive valuations.

In addition, the team prefers companies that generate consistent earnings, cash flow, and income.

Then the manager constructs a diversified portfolio of stocks from a list of companies in the benchmark index favored by the research team and allocates capital based on its conviction level.

The fund is non-diversified, which means it may invest a greater portion of its net assets in the securities of one or more issuers and invests overall in a smaller number of issuers than a diversified fund.

The fund has the flexibility to buy foreign securities that are traded in the U.S. or in foreign markets, as well as American, European, and Global Depositary Receipts.

The fund seeks capital appreciation by investing in small-size companies in the United States.

The investment process is designed to highlight biotechnology companies and discovery research firms.

The investment team considers a biotechnology company or discovery research firm is one that has at least 50% of its earnings derived from biotechnology activities, or at least 50% of its assets devoted to such activities, based on the company’s most recent fiscal year.

Next, the research team considers discovery research firms are in the early stages of drug research.

Also, according to the team biotechnology activities are research, development, manufacture, and distribution of various biotechnological or biomedical products, services, and processes. This may include companies involved with genomics, genetic engineering, gene therapy, and companies involved in the application and development of biotechnology in areas such as health care, pharmaceuticals, and agriculture.

Then the research process is driven by fundamental analysis of one stock at a time. The research team focuses on companies that exhibit future earnings growth potential at attractive valuations.

In addition, the team prefers companies that generate consistent earnings, cash flow, and income.

Then the manager constructs a diversified portfolio of stocks from a list of companies in the benchmark index favored by the research team and allocates capital based on its conviction level.

The fund is non-diversified, which means it may invest a greater portion of its net assets in the securities of one or more issuers and invests overall in a smaller number of issuers than a diversified fund.

The fund has the flexibility to buy foreign securities that are traded in the U.S. or in foreign markets, as well as American, European, and Global Depositary Receipts.

The fund seeks capital appreciation by investing in small-size companies in the United States.

The investment process is designed to highlight biotechnology companies and discovery research firms.

The investment team considers a biotechnology company or discovery research firm is one that has at least 50% of its earnings derived from biotechnology activities, or at least 50% of its assets devoted to such activities, based on the company’s most recent fiscal year.

Next, the research team considers discovery research firms are in the early stages of drug research.

Also, according to the team biotechnology activities are research, development, manufacture, and distribution of various biotechnological or biomedical products, services, and processes. This may include companies involved with genomics, genetic engineering, gene therapy, and companies involved in the application and development of biotechnology in areas such as health care, pharmaceuticals, and agriculture.

Then the research process is driven by fundamental analysis of one stock at a time. The research team focuses on companies that exhibit future earnings growth potential at attractive valuations.

In addition, the team prefers companies that generate consistent earnings, cash flow, and income.

Then the manager constructs a diversified portfolio of stocks from a list of companies in the benchmark index favored by the research team and allocates capital based on its conviction level.

The fund is non-diversified, which means it may invest a greater portion of its net assets in the securities of one or more issuers and invests overall in a smaller number of issuers than a diversified fund.

The fund has the flexibility to buy foreign securities that are traded in the U.S. or in foreign markets, as well as American, European, and Global Depositary Receipts.

The fund seeks capital appreciation in the long term by investing in mid-and large-size companies in the United States.

The investment process is designed to highlight companies that are engaged in the research, development, production, or distribution of products or services related to health care, medicine, or the life sciences.

Next, the research team considers pharmaceutical firms, designers and manufacturers of medical equipment and supplies, operators of hospitals, other health-care services, and biotechnological researchers and developers as related to health science companies.

The research team utilizes quantitative techniques and fundamental analysis to assess a company’s valuation, earnings growth potential, competitive advantages and the expertise of its management team.

Then the research process is driven by fundamental analysis of one stock at a time. The research team narrows the investable universe to a list of companies that are well-positioned to take advantage of technological advances, innovative changes and demographic trends affecting the health science industry.

Then the manager constructs a portfolio of stocks from a list of companies in the benchmark index favored by the research team and allocates capital based on its conviction level.

The manager invests at least 25% of the fund’s net assets in companies doing business in the health science industry, but will regularly invest in health science companies well in excess of this amount.

The fund may invest in real estate investment trusts, securities of foreign companies and American Depositary Receipts.

The fund has the flexibility to invest across all market capitalizations.

The fund seeks capital appreciation by investing in small-and-mid-size companies in the United States.

The investment process is designed to highlight companies that are involved in the biotechnology industry.

The process also includes companies involved in research and development, genetic or other biological engineering, and in the design, manufacture, or sale of related biotechnology products or services.

Then the research team combines a proprietary quantitative and qualitative methodology to identify investment opportunities.

The team utilizes screens based on price, liquidity, and tradability to evaluate potential investments.

Then the manager constructs a diversified portfolio of stocks from a list of companies in the benchmark index favored by the research team and allocates capital based on its conviction level.

The fund also may purchase American Depositary Receipts to gain exposure to foreign biotechnology companies and U.S. government securities.

The fund is non-diversified and may invest a greater percentage of its net assets in a particular issuer in comparison to a diversified fund.

The fund seeks capital appreciation by investing in small-and-mid-size companies in the United States.

The investment process is designed to highlight companies that are involved in the biotechnology industry.

The process also includes companies involved in research and development, genetic or other biological engineering, and in the design, manufacture, or sale of related biotechnology products or services.

Then the research team combines a proprietary quantitative and qualitative methodology to identify investment opportunities.

The team utilizes screens based on price, liquidity, and tradability to evaluate potential investments.

Then the manager constructs a diversified portfolio of stocks from a list of companies in the benchmark index favored by the research team and allocates capital based on its conviction level.

The fund also may purchase American Depositary Receipts to gain exposure to foreign biotechnology companies and U.S. government securities.

The fund is non-diversified and may invest a greater percentage of its net assets in a particular issuer in comparison to a diversified fund.

The fund seeks capital appreciation by investing in small-and-mid-size companies in the United States.

The investment process is designed to highlight companies that are involved in the biotechnology industry.

The process also includes companies involved in research and development, genetic or other biological engineering, and in the design, manufacture, or sale of related biotechnology products or services.

Then the research team combines a proprietary quantitative and qualitative methodology to identify investment opportunities.

The team utilizes screens based on price, liquidity, and tradability to evaluate potential investments.

Then the manager constructs a diversified portfolio of stocks from a list of companies in the benchmark index favored by the research team and allocates capital based on its conviction level.

The fund also may purchase American Depositary Receipts to gain exposure to foreign biotechnology companies and U.S. government securities.

The fund is non-diversified and may invest a greater percentage of its net assets in a particular issuer in comparison to a diversified fund.

The fund seeks capital appreciation by investing in small-and-mid-size companies in the United States.

The investment process is designed to highlight companies that are involved in the biotechnology industry.

The process also includes companies involved in research and development, genetic or other biological engineering, and in the design, manufacture, or sale of related biotechnology products or services.

Then the research team combines a proprietary quantitative and qualitative methodology to identify investment opportunities.

The team utilizes screens based on price, liquidity, and tradability to evaluate potential investments.

Then the manager constructs a diversified portfolio of stocks from a list of companies in the benchmark index favored by the research team and allocates capital based on its conviction level.

The fund also may purchase American Depositary Receipts to gain exposure to foreign biotechnology companies and U.S. government securities.

The fund is non-diversified and may invest a greater percentage of its net assets in a particular issuer in comparison to a diversified fund.

The fund seeks capital appreciation by investing in small-and mid-size companies in the United States.

The investment process is designed to highlight companies that are engaged in the health care industry.

The investment team considers pharmaceutical companies, companies involved in the research and development of pharmaceutical products and services, companies involved in the operation of health care facilities as related to health care companies.

The team also considers companies involved in the design, manufacture, or sale of health care related products or services as related to health care companies.

Then the research team combines a proprietary quantitative and qualitative methodology to identify investment opportunities.

The team utilizes screens based on price, liquidity, and tradability to evaluate potential investments.

Then the manager constructs a diversified portfolio of stocks from a list of companies in the benchmark index favored by the research team and allocates capital based on its conviction level.

The fund also may purchase American Depositary Receipts to gain exposure to foreign health care companies and U.S. government securities.

The fund seeks capital appreciation by investing in small-and mid-size companies in the United States.

The investment process is designed to highlight companies that are engaged in the health care industry.

The investment team considers pharmaceutical companies, companies involved in the research and development of pharmaceutical products and services, companies involved in the operation of health care facilities as related to health care companies.

The team also considers companies involved in the design, manufacture, or sale of health care related products or services as related to health care companies.

Then the research team combines a proprietary quantitative and qualitative methodology to identify investment opportunities.

The team utilizes screens based on price, liquidity, and tradability to evaluate potential investments.

Then the manager constructs a diversified portfolio of stocks from a list of companies in the benchmark index favored by the research team and allocates capital based on its conviction level.

The fund also may purchase American Depositary Receipts to gain exposure to foreign health care companies and U.S. government securities.

The fund seeks capital appreciation by investing in small-and mid-size companies in the United States.

The investment process is designed to highlight companies that are engaged in the health care industry.

The investment team considers pharmaceutical companies, companies involved in the research and development of pharmaceutical products and services, companies involved in the operation of health care facilities as related to health care companies.

The team also considers companies involved in the design, manufacture, or sale of health care related products or services as related to health care companies.

Then the research team combines a proprietary quantitative and qualitative methodology to identify investment opportunities.

The team utilizes screens based on price, liquidity, and tradability to evaluate potential investments.

Then the manager constructs a diversified portfolio of stocks from a list of companies in the benchmark index favored by the research team and allocates capital based on its conviction level.

The fund also may purchase American Depositary Receipts to gain exposure to foreign health care companies and U.S. government securities.

The fund seeks capital appreciation by investing in small-and mid-size companies in the United States.

The investment process is designed to highlight companies that are engaged in the health care industry.

The investment team considers pharmaceutical companies, companies involved in the research and development of pharmaceutical products and services, companies involved in the operation of health care facilities as related to health care companies.

The team also considers companies involved in the design, manufacture, or sale of health care related products or services as related to health care companies.

Then the research team combines a proprietary quantitative and qualitative methodology to identify investment opportunities.

The team utilizes screens based on price, liquidity, and tradability to evaluate potential investments.

Then the manager constructs a diversified portfolio of stocks from a list of companies in the benchmark index favored by the research team and allocates capital based on its conviction level.

The fund also may purchase American Depositary Receipts to gain exposure to foreign health care companies and U.S. government securities.

The fund seeks capital appreciation in the long term by investing in companies across any size in the United States.

The investment process is designed to highlight companies that are engaged in the healthcare and biotechnology industries.

The investment team emphasizes companies engaged in: the design, manufacture or sale of products or services used for or in connection with health, medical, or personal care such as medical, dental and optical supplies or equipment; research and development of pharmaceutical products and services.

Other companies that the team focuses on are involved in the operation of healthcare facilities such as hospitals, clinical test laboratories and convalescent and mental healthcare facilities; and the design, manufacture, or sale of healthcare-related products and services.

Next, the research team utilizes a top-down process to identify long-term economic trends. The team focuses on specific industries with attractive characteristics and long-term growth potential.

Additionally, the research team narrows the investable universe to a list of high-quality companies within the selected industries and buys them at reasonable valuations.

Then the research process is driven by fundamental analysis of one stock at a time. The research team assesses a company’s valuation, earnings growth potential, competitive advantages and the expertise of its management team.

Then the manager constructs a diversified portfolio of stocks from a list of companies in the benchmark index favored by the research team and allocates capital based on its conviction level.

The fund seeks capital appreciation in the long term by investing in companies across any size in the United States.

The investment process is designed to highlight companies that are engaged in the healthcare and biotechnology industries.

The investment team emphasizes companies engaged in: the design, manufacture or sale of products or services used for or in connection with health, medical, or personal care such as medical, dental and optical supplies or equipment; research and development of pharmaceutical products and services.

Other companies that the team focuses on are involved in the operation of healthcare facilities such as hospitals, clinical test laboratories and convalescent and mental healthcare facilities; and the design, manufacture, or sale of healthcare-related products and services.

Next, the research team utilizes a top-down process to identify long-term economic trends. The team focuses on specific industries with attractive characteristics and long-term growth potential.

Additionally, the research team narrows the investable universe to a list of high-quality companies within the selected industries and buys them at reasonable valuations.

Then the research process is driven by fundamental analysis of one stock at a time. The research team assesses a company’s valuation, earnings growth potential, competitive advantages and the expertise of its management team.

Then the manager constructs a diversified portfolio of stocks from a list of companies in the benchmark index favored by the research team and allocates capital based on its conviction level.

The fund seeks capital appreciation in the long term by investing in companies across any size in the United States.

The investment process is designed to highlight companies that are engaged in the healthcare and biotechnology industries.

The investment team emphasizes companies engaged in: the design, manufacture or sale of products or services used for or in connection with health, medical, or personal care such as medical, dental and optical supplies or equipment; research and development of pharmaceutical products and services.

Other companies that the team focuses on are involved in the operation of healthcare facilities such as hospitals, clinical test laboratories and convalescent and mental healthcare facilities; and the design, manufacture, or sale of healthcare-related products and services.

Next, the research team utilizes a top-down process to identify long-term economic trends. The team focuses on specific industries with attractive characteristics and long-term growth potential.

Additionally, the research team narrows the investable universe to a list of high-quality companies within the selected industries and buys them at reasonable valuations.

Then the research process is driven by fundamental analysis of one stock at a time. The research team assesses a company’s valuation, earnings growth potential, competitive advantages and the expertise of its management team.

Then the manager constructs a diversified portfolio of stocks from a list of companies in the benchmark index favored by the research team and allocates capital based on its conviction level.

The fund seeks capital appreciation in the long term by investing in companies in the United States.

The investment process is designed to highlight companies in the benchmark index that are engaged in the health care sector.

The process focuses on health care companies, such as pharmaceuticals and biotechnology companies, health care facilities operations, and medical product manufacturers and suppliers, and medical providers and medical services firms.

Then the investment team relies on quantitative techniques to evaluate securities based on three components such as fundamentals, valuation, and momentum.

Next, the research team selects portfolio securities utilizing the Schwab Equity Ratings, a model that assigns ratings to approximately 3,000 of the largest traded stocks.

In addition, the research team utilizes investment data and other analytics to assess a company.

Then the manager constructs a portfolio of stocks that are highly rated by Schwab Equity Ratings. Additionally, the manager purchases lower-rated stocks for purposes of diversification, or for managing the fund’s liquidity, turnover, or volatility relative to the Index.

Also, the portfolio optimization process provides the optimal balance between risk and expected return subject to factors such as the number of stocks desired in the portfolio, the level of portfolio turnover, industry and sector diversification, and volatility considerations.

The fund may invest in derivatives, principally futures contracts primarily to seek returns on the fund’s otherwise uninvested cash assets.

The fund also may lend portfolio securities to earn additional income.

The fund may invest up to 100% of its assets in cash, money market instruments, repurchase agreements and other short-term obligations for temporary defensive purposes during unusual economic or market conditions or for liquidity purposes.

The fund may invest up to 25% of its net assets in non-U.S. companies located in developed market countries; however, it may also invest in companies located in emerging markets.

The fund seeks capital appreciation in the long term by investing in large-and mid-size companies in the United States.

The investment process is designed to highlight companies in the benchmark index that are engaged in the health sciences companies.

The process focuses on companies engaged in the research, development, production, or distribution of products or services related to health care, medicine, or the life sciences.

Then the research team relies on fundamental analysis to identify high-quality companies that represent the most compelling investment opportunities.

The team considers companies with rapid earnings growth relative to inflation and the economy. In addition, the team seeks companies that are estimated to trade below their fair values.

The fund may seek investments in companies that are developing new and effective medicines, as well as companies whose business models reduce costs or improve quality in health care systems.

Then the manager constructs a diversified portfolio of stocks from a list of companies in the benchmark index favored by the research team and allocates capital based on its conviction level.

The manager divides the health sciences sector into four main areas namely pharmaceutical companies; health care services companies; medical products and devices providers; and biotechnology firms.

Next, the manager allocates capital depending on the relative potential within each area and the outlook for the overall health sciences sector.

The fund may purchase a security if it believes there could be an increase in value as a result of an extraordinary corporate event, a new product introduction or innovation, a favorable competitive development, or a management change.

The fund has the flexibility to invest across all market capitalizations.

The fund is non-diversified and may invest a greater percentage of its net assets in fewer issuers than a diversified fund.

The fund seeks capital appreciation in the long term by investing in large-and mid-size companies in the United States.

The investment process is designed to highlight companies in the benchmark index that are engaged in the health sciences companies.

The process focuses on companies engaged in the research, development, production, or distribution of products or services related to health care, medicine, or the life sciences.

Then the research team relies on fundamental analysis to identify high-quality companies that represent the most compelling investment opportunities.

The team considers companies with rapid earnings growth relative to inflation and the economy. In addition, the team seeks companies that are estimated to trade below their fair values.

The fund may seek investments in companies that are developing new and effective medicines, as well as companies whose business models reduce costs or improve quality in health care systems.

Then the manager constructs a diversified portfolio of stocks from a list of companies in the benchmark index favored by the research team and allocates capital based on its conviction level.

The manager divides the health sciences sector into four main areas namely pharmaceutical companies; health care services companies; medical products and devices providers; and biotechnology firms.

Next, the manager allocates capital depending on the relative potential within each area and the outlook for the overall health sciences sector.

The fund may purchase a security if it believes there could be an increase in value as a result of an extraordinary corporate event, a new product introduction or innovation, a favorable competitive development, or a management change.

The fund has the flexibility to invest across all market capitalizations.

The fund is non-diversified and may invest a greater percentage of its net assets in fewer issuers than a diversified fund.

The fund seeks to track the total return performance of a benchmark index before fees and expenses by investing in companies across any size in the United States.

The investment process starts with a list of companies in the benchmark index and the research team utilizes quantitative techniques and fundamental analysis to identify investment opportunities.

The process employs an indexing investment approach to track the performance of the MSCI US Investable Market Index (IMI)/Health Care 25/50 Index.

Next, the research team focuses on companies that are engaged in the health care sector, which includes companies involved in providing medical or health care products, services, technology, or equipment.

The team follows the GICS health care sector classification which includes health care provider and services companies, companies that manufacture and distribute health care equipment and supplies, and health care technology companies.

The GICS health care sector classification also includes companies involved in the research, development, production, and marketing of pharmaceuticals and biotechnology products.

Then the manager constructs a diversified portfolio from a list of companies favored by the research team and allocates capital based on its conviction level.

The fund seeks to replicate the composition of the benchmark index, holding each security in approximately the same proportion as its weighting in the Index.

The fund seeks capital appreciation in the long term by investing in companies across any size in the United States.

The sub-advisor’s investment process is designed to highlight stocks of health sciences-related companies.

The investment team considers health sciences-related companies to include companies that design, manufacture or sell products or services used for or in connection with healthcare, medicine or life sciences.

The fund seeks to capitalize on the rapid growth in global healthcare spending due to impact from COVID-19, coupled with an aging society.

Next, the research team prefers companies demonstrating above-average growth and superior capital appreciation potential.

The team also considers companies exhibiting substantial capacity for growth in revenue through either an expanding market or market share; balance sheet strength; and superior management.

In addition; the team also looks for companies with a dedication to research and product development; and differentiated or superior products and services or a consistent flow of new products and services.

Then the manager constructs a diversified portfolio from a list of companies in the benchmark index favored by the research team and allocates capital based on its conviction level.

Stock selection and portfolio construction is driven by high conviction growth, quality, valuation, and ESG risk criteria.

The portfolio holds 45 to 75 high-quality healthcare companies, addressing themes such as innovative biotechnology and pharmacological treatments, cost-effective medical solutions, preventative health care, and healthy lifestyles.

The fund may invest in U.S. and non-U.S. companies, and may invest up to 15% of its net assets in emerging market securities but no more than 10% in any one emerging market country.

The fund may invest in securities issued in initial public offerings.

The fund seeks capital appreciation in the long term by investing in companies across any size in the United States.

The sub-advisor’s investment process is designed to highlight stocks of health sciences-related companies.

The investment team considers health sciences-related companies to include companies that design, manufacture or sell products or services used for or in connection with healthcare, medicine or life sciences.

The fund seeks to capitalize on the rapid growth in global healthcare spending due to impact from COVID-19, coupled with an aging society.

Next, the research team prefers companies demonstrating above-average growth and superior capital appreciation potential.

The team also considers companies exhibiting substantial capacity for growth in revenue through either an expanding market or market share; balance sheet strength; and superior management.

In addition; the team also looks for companies with a dedication to research and product development; and differentiated or superior products and services or a consistent flow of new products and services.

Then the manager constructs a diversified portfolio from a list of companies in the benchmark index favored by the research team and allocates capital based on its conviction level.

Stock selection and portfolio construction is driven by high conviction growth, quality, valuation, and ESG risk criteria.

The portfolio holds 45 to 75 high-quality healthcare companies, addressing themes such as innovative biotechnology and pharmacological treatments, cost-effective medical solutions, preventative health care, and healthy lifestyles.

The fund may invest in U.S. and non-U.S. companies, and may invest up to 15% of its net assets in emerging market securities but no more than 10% in any one emerging market country.

The fund may invest in securities issued in initial public offerings.

The fund seeks capital appreciation in the long term by investing in companies across any size in the United States.

The sub-advisor’s investment process is designed to highlight stocks of health sciences-related companies.

The investment team considers health sciences-related companies to include companies that design, manufacture or sell products or services used for or in connection with healthcare, medicine or life sciences.

The fund seeks to capitalize on the rapid growth in global healthcare spending due to impact from COVID-19, coupled with an aging society.

Next, the research team prefers companies demonstrating above-average growth and superior capital appreciation potential.

The team also considers companies exhibiting substantial capacity for growth in revenue through either an expanding market or market share; balance sheet strength; and superior management.

In addition; the team also looks for companies with a dedication to research and product development; and differentiated or superior products and services or a consistent flow of new products and services.

Then the manager constructs a diversified portfolio from a list of companies in the benchmark index favored by the research team and allocates capital based on its conviction level.

Stock selection and portfolio construction is driven by high conviction growth, quality, valuation, and ESG risk criteria.

The portfolio holds 45 to 75 high-quality healthcare companies, addressing themes such as innovative biotechnology and pharmacological treatments, cost-effective medical solutions, preventative health care, and healthy lifestyles.

The fund may invest in U.S. and non-U.S. companies, and may invest up to 15% of its net assets in emerging market securities but no more than 10% in any one emerging market country.

The fund may invest in securities issued in initial public offerings.